SYNGENE INTERNATIONAL Latest Share Price (SYNGENE)
TODAY IN ONE LINE
SYNGENE fell 2.0% on light volume, lagging Nifty's -0.4% move.
With a market cap of ₹15,266.77 Cr., it trades at a P/E of 68.89. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SYNGENE INTERNATIONAL flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 19.5% YoY
- ●Sales ContractionQuarterly sales dropped 9.9% YoY
- ●Poor Capital ReturnsLow ROE of 6.5%
- ●Expensive ValuationTrading at a high P/E ratio of 55.0x
- ●FII SellingFII holding decreased by 2.08% QoQ
- ●Promoter SellingPromoter holding decreased by 0.29% QoQ
- ●Rising Receivables vs SalesReceivables grew 17.4% outpacing sales growth of 4.4%
Latest SYNGENE INTERNATIONAL News
What changed recently?
Recent events, corporate actions, and announcements.
SYNGENE INTERNATIONAL valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SYNGENE INTERNATIONAL, framed against the sector median so the premium or discount is obvious at a glance.
SYNGENE INTERNATIONAL trades at a P/E of 68.89× and P/B of 3.15×, against the Healthcare sector median P/E of 46.64×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SYNGENE INTERNATIONAL technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SYNGENE INTERNATIONAL — derived from the latest tape, not yesterday's close.
SYNGENE INTERNATIONAL last traded at ₹377.5 with an intraday range of ₹373.6–₹385.85 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹377.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 408.87 | +31.37 | +8.31% |
| R3 | 396.62 | +19.12 | +5.06% |
| R2 | 391.23 | +13.73 | +3.64% |
| R1 | 384.37 | +6.87 | +1.82% |
| PIVOT | 378.98 | 1.48 | 0.39% |
| CURRENT | 377.50 | — | — |
| S1 | 372.12 | -5.38 | -1.43% |
| S2 | 366.73 | -10.77 | -2.85% |
| S3 | 359.87 | -17.63 | -4.67% |
| S4 | 347.62 | -29.88 | -7.92% |
SYNGENE is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹382–₹385.85
Trading Inside opening range
SYNGENE INTERNATIONAL financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SYNGENE INTERNATIONAL — consolidated or standalone — with margins, YoY growth and key ratios inline.
SYNGENE INTERNATIONAL reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹15,266.77 Cr. and reported EPS of ₹-0.05.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 3,642 | 3,739 ▲ 2.6% |
| Sales Growth YoY %Derived | 4.41% | 2.64% |
| Other Income | 72 | 71 ▼ 1.5% |
| Total Income | 3,714 | 3,809 ▲ 2.6% |
| 943 | 919 ▼ 2.5% | |
| Gross ProfitDerived | 2,700 | 2,820 ▲ 4.5% |
| Gross Margin %Derived | 74.12% | 75.43% |
| 1,658 | 1,902 ▲ 14.7% | |
| EBITDA (Operating Profit)Derived | 1,042 | 919 ▼ 11.8% |
| OPM %Derived | 28.60% | 24.57% |
| 518 | 425 ▼ 17.9% | |
| Profit Before Tax (PBT) | 660 | 411 ▼ 37.7% |
| 164 | 94 ▼ 42.5% | |
| Effective Tax %Derived | 24.81% | 22.93% |
| Total Profit for Period | 496 | 317 ▼ 36.2% |
| Net Profit (Owner's PAT)Derived | 496 | 317 ▼ 36.2% |
| Net Profit Margin %Derived | 13.62% | 8.47% |
| PAT Growth YoY %Derived | -2.71% | -36.17% |
| Earnings Per Share (EPS ₹) | 12.33 | 7.86 ▼ 36.3% |
| Diluted Shares Outstanding (Cr) | 40 | 40 ▲ 0.1% |
| Other Comprehensive Income (Net of Tax) | -15 | -196 ▼ 1233.3% |
| Total Expenses (incl. D&A & Interest) | 3,054 | 3,399 ▲ 11.3% |
| Material Cost % of RevenueDerived | 25.41% | 24.37% |
| Employee Cost % of RevenueDerived | 27.01% | 29.55% |
| Other Cost % of RevenueDerived | 18.51% | 21.31% |
| Interest Coverage (x)Derived | 11.47x | 9.54x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,826 | 2,012 ▲ 10.2% | 2,184 ▲ 8.6% | 2,604 ▲ 19.2% | 3,193 ▲ 22.6% | 3,489 ▲ 9.3% | 3,642 ▲ 4.4% | 3,739 ▲ 2.6% | |
| Sales Growth YoY %Derived | — | 10.20% | 8.57% | 19.22% | 22.61% | 9.26% | 4.41% | 2.64% | |
| Other Income | 75 | 82 ▲ 8.7% | 65 ▼ 20.8% | 53 ▼ 18.3% | 71 ▲ 34.3% | 91 ▲ 27.8% | 72 ▼ 20.8% | 71 ▼ 1.5% | |
| Total Income | 1,901 | 2,094 ▲ 10.1% | 2,249 ▲ 7.4% | 2,657 ▲ 18.1% | 3,264 ▲ 22.8% | 3,579 ▲ 9.7% | 3,714 ▲ 3.8% | 3,809 ▲ 2.6% | |
531 | 519 ▼ 2.2% | 527 ▲ 1.4% | 749 ▲ 42.3% | 860 ▲ 14.8% | 930 ▲ 8.1% | 943 ▲ 1.3% | 919 ▼ 2.5% | ||
| Gross ProfitDerived | 1,294 | 1,493 ▲ 15.3% | 1,658 ▲ 11.1% | 1,855 ▲ 11.9% | 2,333 ▲ 25.7% | 2,558 ▲ 9.7% | 2,700 ▲ 5.5% | 2,820 ▲ 4.5% | |
| Gross Margin %Derived | 70.90% | 74.18% | 75.90% | 71.24% | 73.06% | 73.34% | 74.12% | 75.43% | |
758 | 875 ▲ 15.5% | 986 ▲ 12.7% | 1,059 ▲ 7.4% | 1,398 ▲ 32.0% | 1,544 ▲ 10.4% | 1,658 ▲ 7.4% | 1,902 ▲ 14.7% | ||
| EBITDA (Operating Profit)Derived | 537 | 618 ▲ 15.1% | 672 ▲ 8.7% | 796 ▲ 18.5% | 934 ▲ 17.4% | 1,014 ▲ 8.6% | 1,042 ▲ 2.7% | 919 ▼ 11.8% | |
| OPM %Derived | 29.40% | 30.71% | 30.76% | 30.57% | 29.26% | 29.08% | 28.60% | 24.57% | |
197 | 325 ▲ 65.5% | 337 ▲ 3.7% | 303 ▼ 10.1% | 412 ▲ 35.8% | 462 ▲ 12.2% | 518 ▲ 12.1% | 425 ▼ 17.9% | ||
| Profit Before Tax (PBT) | 415 | 517 ▲ 24.4% | 469 ▼ 9.2% | 484 ▲ 3.2% | 594 ▲ 22.5% | 621 ▲ 4.6% | 660 ▲ 6.3% | 411 ▼ 37.7% | |
84 | 105 ▲ 25.1% | 64 ▼ 38.6% | 89 ▲ 37.8% | 129 ▲ 45.8% | 111 ▼ 14.2% | 164 ▲ 47.7% | 94 ▼ 42.5% | ||
| Effective Tax %Derived | 20.17% | 20.27% | 13.70% | 18.29% | 21.77% | 17.85% | 24.81% | 22.93% | |
| Total Profit for Period | 332 | 412 ▲ 24.3% | 405 ▼ 1.7% | 396 ▼ 2.2% | 464 ▲ 17.3% | 510 ▲ 9.8% | 496 ▼ 2.7% | 317 ▼ 36.2% | |
| Net Profit (Owner's PAT)Derived | 332 | 412 ▲ 24.3% | 405 ▼ 1.7% | 396 ▼ 2.2% | 464 ▲ 17.3% | 510 ▲ 9.8% | 496 ▼ 2.7% | 317 ▼ 36.2% | |
| Net Profit Margin %Derived | 18.16% | 20.48% | 18.54% | 15.20% | 14.54% | 14.62% | 13.62% | 8.47% | |
| PAT Growth YoY %Derived | — | 24.28% | -1.75% | -2.25% | 17.33% | 9.82% | -2.71% | -36.17% | |
| Earnings Per Share (EPS ₹) | 8.29 | 10.30 ▲ 24.2% | 10.12 ▼ 1.7% | 9.88 ▼ 2.4% | 11.57 ▲ 17.1% | 12.69 ▲ 9.7% | 12.33 ▼ 2.8% | 7.86 ▼ 36.3% | |
| Diluted Shares Outstanding (Cr) | 40 | 40 ▲ 0.0% | 40 ▲ 0.0% | 40 ▲ 0.2% | 40 ▲ 0.2% | 40 ▲ 0.1% | 40 ▲ 0.1% | 40 ▲ 0.1% | |
| Other Comprehensive Income (Net of Tax) | -70 | -192 ▼ 172.9% | 191 ▲ 199.5% | 43 ▼ 77.3% | -97 ▼ 324.5% | 143 ▲ 246.7% | -15 ▼ 110.3% | -196 ▼ 1233.3% | |
| Total Expenses (incl. D&A & Interest) | 1,485 | 1,577 ▲ 6.1% | 1,780 ▲ 12.9% | 2,173 ▲ 22.1% | 2,670 ▲ 22.9% | 2,958 ▲ 10.8% | 3,054 ▲ 3.2% | 3,399 ▲ 11.3% | |
| Material Cost % of RevenueDerived | 27.68% | 25.78% | 25.26% | 29.59% | 28.26% | 25.04% | 25.41% | 24.37% | |
| Employee Cost % of RevenueDerived | 25.89% | 28.85% | 30.22% | 27.57% | 26.36% | 25.47% | 27.01% | 29.55% | |
| Other Cost % of RevenueDerived | 15.60% | 14.62% | 14.92% | 13.09% | 17.43% | 18.78% | 18.51% | 21.31% | |
| Interest Coverage (x)Derived | 11.54x | 11.52x | 14.34x | 20.18x | 12.56x | 12.47x | 11.47x | 9.54x |
SYNGENE INTERNATIONAL segment analysis : revenue and profit mix.
Disclosed business segments at SYNGENE INTERNATIONAL with their share of revenue and profit, switchable between consolidated and standalone reporting.
SYNGENE INTERNATIONAL discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SYNGENE INTERNATIONAL.
Our AI distills the core fundamental drivers supporting SYNGENE INTERNATIONAL, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
SYNGENE INTERNATIONAL's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 90 (~1.9× the sector multiple of 46.6) would leave less room for earnings disappointment.
Fundamental risk. a shrinking deal pipeline (TCV) or margins below historical averages would weaken the thesis.
Watch wage inflation and attrition rates — primary threats to operating leverage in IT.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
SYNGENE INTERNATIONAL peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SYNGENE INTERNATIONAL is highlighted for quick read-across.
Quick Compare
SYNGENE INTERNATIONAL chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SYNGENE INTERNATIONAL — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SYNGENE INTERNATIONAL delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SYNGENE INTERNATIONAL over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SYNGENE INTERNATIONAL stood at 47.4% of traded volume, against a 20-day average of 54.9%.
SYNGENE INTERNATIONAL announcements: results, concalls, ratings, M&A.
Filings SYNGENE INTERNATIONAL sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SYNGENE INTERNATIONAL files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 244 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Syngene International Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Syngene International Limited has informed the Exchange about Schedule of meet
General Updates
Syngene International Limited has informed the Exchange about the Communication regarding remittance of final dividend for the FY 2025-26.
Analysts/Institutional Investor Meet/Con. Call Updates
Syngene International Limited has informed the Exchange about Schedule of meet
Acquisition
Syngene International Limited has informed the Exchange about Acquisition
Investor decks & rating reports.
SYNGENE INTERNATIONAL dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SYNGENE INTERNATIONAL has declared, sequenced by announce and record date.
SYNGENE INTERNATIONAL corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
SYNGENE INTERNATIONAL insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in SYNGENE INTERNATIONAL as reported to SEBI — buying and selling signals from the people who know the business best.
SYNGENE INTERNATIONAL insider activity below tracks 3 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| ANJAN CHAKRABARTI | Insider | 27 Dec 2024 | sell | −6.2 K | ₹52.65 L | ₹850.59 |
| ANJAN CHAKRABARTI | Insider | 20 Dec 2024 | sell | −27.2 K | ₹2.29 Cr. | ₹843.54 |
| ANJAN CHAKRABARTI | Insider | 19 Dec 2024 | buy | +58.4 K | ₹5.02 Cr. | ₹859.73 |
About SYNGENE INTERNATIONAL: business, sector, key facts.
What SYNGENE INTERNATIONAL does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SYNGENE INTERNATIONAL operates in the Healthcare Research Analytics & Technology industry under the Healthcare sector, listed as NSE: SYNGENE, BSE: 539268.
Syngene International Limited is a leading contract research and manufacturing organization (CRO/CMO) with a global presence, offering a comprehensive suite of services across the drug discovery and development value chain. Their services span diverse therapeutic areas and cater to a wide range of clients including pharmaceutical, biotechnology, animal health, and other industries. Their geographical reach extends to India, the United States, Europe, and other international markets, highlighting their established global network and capacity.
Syngene's services in drug discovery encompass a broad spectrum, from early-stage research to preclinical development. This includes expertise in discovery chemistry (synthetic and medicinal chemistry, library and peptide synthesis, etc.), discovery biology (recombinant DNA engineering, cell line development, and various other biological assays), and computational and analytical chemistry. They also provide lead generation services crucial for initiating drug development pipelines.
Beyond drug discovery, Syngene offers extensive development and manufacturing capabilities. Their services include chemical, formulation, analytical, and clinical development, along with commercial manufacturing and sterile fill-finish capabilities. This ensures a seamless transition from discovery to commercialization for their clients. They also provide crucial support services for clinical trials, including management, data management, bioanalysis, and regulatory support.
Syngene's capabilities extend beyond traditional small molecule therapeutics. They possess expertise in biologics, peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization technologies, showcasing their adaptability to emerging therapeutic modalities. Their integrated approach combining chemistry, biology, safety assessment, computational, and data sciences provides a holistic solution for clients seeking comprehensive drug development partnerships.
The company boasts significant collaborations with prominent pharmaceutical giants such as Bristol-Myers Squibb, Baxter Inc., and Amgen Inc., underscoring its reputation and the quality of services provided. Established in 1993 and headquartered in Bengaluru, India, Syngene is a subsidiary of Biocon Limited, benefiting from the parent company's experience and resources within the broader pharmaceutical landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- INDEGENE (INDGN) Share PricePeer
- SUVEN LIFE SCIENCES (SUVEN) Share PricePeer
- TAKE (TAKE) Share PricePeer
- VIMTA LABS (VIMTALABS) Share PricePeer
- Stocks near 52-week low (reversal watch)Screener
- Reversal Hunter strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SYNGENE INTERNATIONAL (SYNGENE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SYNGENE INTERNATIONAL (SYNGENE)?
The current share price of SYNGENE INTERNATIONAL (SYNGENE) is ₹377.50. Today, the stock has declined by ₹7.65 (1.99%), trading in a range of ₹373.60 to ₹385.85. The stock opened at ₹385.15 with a trading volume of 4,22,362 shares.
02Is SYNGENE INTERNATIONAL stock a good investment for long-term?
SYNGENE INTERNATIONAL can be considered for long-term investment based on several factors. The company has a market capitalization of ₹15,266.77 Cr., P/E ratio of 68.89, ROE of 6.54%, and ROCE of 7.51%. The dividend yield stands at 0.34%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SYNGENE INTERNATIONAL stock?
The 52-week high price of SYNGENE INTERNATIONAL (SYNGENE) is ₹678.95, while the 52-week low is ₹360.40. Currently trading at ₹377.50, the stock is 4.74% above its 52-week low and 44.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SYNGENE INTERNATIONAL stock at the current price?
Whether to buy SYNGENE INTERNATIONAL stock at ₹377.50 depends on multiple factors. The stock is currently trading with a P/E ratio of 68.89 and P/B ratio of 3.15. Today's performance shows a loss of 1.99%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SYNGENE INTERNATIONAL and when is the next dividend?
SYNGENE INTERNATIONAL offers a dividend yield of 0.34%, which means for every ₹100 invested at the current price of ₹377.50, you can expect to receive approximately ₹0.34 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SYNGENE INTERNATIONAL?
SYNGENE INTERNATIONAL's key financial metrics include: P/E Ratio: 68.89, P/B Ratio: 3.15, ROE: 6.54%, ROCE: 7.51%, Dividend Yield: 0.34%, EPS: ₹-0.05, Book Value: ₹119.88, and Debt-to-Equity: 0. The company's market cap stands at ₹15,266.77 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SYNGENE INTERNATIONAL stock performing today in the market?
SYNGENE INTERNATIONAL stock opened at ₹385.15 and is currently trading at ₹377.50, showing a decline of ₹7.65 (1.99%). The intraday high is ₹385.85 and low is ₹373.60. The trading volume stands at 4,22,362 shares, indicating moderate market participation today.
08What is the P/E ratio of SYNGENE INTERNATIONAL and what does it indicate?
SYNGENE INTERNATIONAL has a Price-to-Earnings (P/E) ratio of 68.89, which means investors are willing to pay 68.89 for every ₹1 of earnings. With an EPS of ₹-0.05, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SYNGENE INTERNATIONAL (SYNGENE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.